Coreline Soft has secured FDA 510(k) clearance for AVIEW Aorta Metrics, marking the South Korean company's 13th regulatory approval in the United States and its strategic expansion from pulmonary imaging into cardiovascular diagnostics. The clearance, granted October 16 and announced October 26, 2024, enables automated aortic segmentation and quantitative measurement from routine chest CT scans—a capability that could transform how clinicians detect cardiovascular abnormalities through opportunistic screening.

Multi-Disease Platform Strategy Takes Shape

AVIEW Aorta Metrics automatically segments the aorta from chest CT images, classifies anatomical zones, and measures diameter across each zone while providing straightened curved planar reformation (CPR), cross-sectional views, 3D visualization, and analysis reports. The software integrates into Coreline Soft's broader AVIEW platform, which already includes FDA-cleared products for lung cancer screening (AVIEW LCS), lung nodule detection and quantitative analysis (AVIEW Lung Nodule CAD), and coronary artery calcium scoring from non-contrast chest CT (AVIEW CAC).

This multi-disease approach allows healthcare providers to extract multiple diagnostic insights from a single chest CT scan ordered for any clinical indication. By layering cardiovascular assessment onto existing pulmonary imaging workflows, the platform addresses growing demand for quantitative imaging biomarkers without requiring additional radiation exposure or separate imaging studies.

The company has established strategic partnerships designed to accelerate clinical adoption. Its collaboration with INFINITT North America enables PACS-integrated "zero-click" automation that reduces radiologist workflow burden. Partnerships with Optellum support lung nodule management pathway integration, while collaboration with Oatmeal Health targets lung cancer risk assessment and U.S. reimbursement pathways.

Opportunistic Screening Meets Clinical Workflow

The cardiovascular expansion positions Coreline Soft to capitalize on opportunistic screening—the practice of extracting additional diagnostic value from imaging studies ordered for unrelated reasons. AVIEW Aorta Metrics enables detection of aortic abnormalities including aneurysms, dissections, and atherosclerotic disease from chest CTs performed for trauma evaluation, cancer staging, or pulmonary assessment.

For radiologists, the zero-click PACS integration promises to deliver quantitative aortic measurements automatically, potentially improving detection rates for incidental findings while maintaining existing workflow efficiency. For patients, the technology offers earlier identification of cardiovascular pathology without additional healthcare costs or radiation exposure.

Coreline Soft plans to showcase its expanded platform at RSNA 2024, scheduled for November 29 through December 3 at McCormick Place in Chicago. The company will exhibit at AI Showcase Booth #5138 in South Hall, Level 3, under the theme "From AI Detection to Clinical Implementation."

Competitive Positioning in Quantitative Imaging

With 13 FDA clearances now secured, Coreline Soft's multi-organ analysis strategy from single imaging modalities differentiates the company from specialized cardiovascular AI vendors and positions it within the competitive landscape of comprehensive radiology AI platforms. The shift from point-solution AI tools toward integrated clinical pathway solutions—evidenced by strategic partnerships spanning PACS vendors, clinical decision support platforms, and reimbursement-focused organizations—signals the company's ambition to move beyond algorithmic development into sustainable clinical implementation.

Whether this platform approach offers durable competitive advantage against larger radiology AI vendors or specialized cardiovascular imaging companies remains to be demonstrated through real-world adoption metrics and clinical outcomes data.

Sources

  1. Coreline Soft Secures 13th US FDA Clearance, Expanding AI-Powered CT Imaging into Aortic Assessment — biopharmaapac.com